IPO Ideas
Anlon Healthcare Limited IPO logo

Anlon Healthcare Limited IPO

BBMainboardBSE, NSEListed
Listed at
92
+1.10%

Anlon Healthcare Limited IPO is a Mainboard book building IPO. Price band is ₹91 per share. Minimum investment is ₹14,924. Lot size is 164 shares. Open from 26 Aug 2025 to 29 Aug 2025. Allotment on 1 Sept 2025. Listing on 3 Sept 2025 at BSE, NSE. Managed by Interactive Financial Services Ltd.. Registrar: Kfin Technologies Limited. Key details for GMP, subscription, price, allotment, and listing in one place.

Official documents: RHP and DRHP.

Anlon Healthcare Limited IPO overview

Anlon Healthcare Limited IPO Key figures

Price band, lot, minimum application, and issue window at a glance.

Price band
₹91
Lot size
164 shares / lot
Min investment
₹14,924
Issue open – close
26 Aug 2025 → 29 Aug 2025

Anlon Healthcare Limited IPO important dates

Issue Opens
26 Aug 2025
Issue Closes
29 Aug 2025
Allotment
1 Sept 2025
Listing
3 Sept 2025

Anlon Healthcare Limited IPO lot size

CategoryLotsSharesAmount
Retail (Min)116414,924
Retail (Max)132,1321,94,012
S-HNI (Min)142,2962,08,936
S-HNI (UPI)335,4124,92,492
S-HNI (Max)6710,9889,99,908
B-HNI (Min)6811,15210,14,832

About Anlon Healthcare Limited IPO

From the company / RHP narrative.

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).

The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).

The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.

In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.

The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.

The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.

The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.

Products:


Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.


Competitive Strengths:


Strong product portfolio and scalable business.
Strong Promoters and Experienced Management Team.
High entry and exit barriers due to long customer approval cycles and strict product standards.
In-house Testing, Quality Control and Quality Assurance for quality control.
Focus on Quality, Environment, Health and Safety.

Objective of the issue

How the issuer plans to use IPO proceeds.

Funding capital expenditure requirements for Proposed Expansion

Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company

Funding the working capital requirements of the Company

General corporate purposes
Anlon Healthcare Limited IPO FAQs
A quick overview of key terms, dates, and how to track this IPO.

Documents & links

Prospectus, draft filings, and company site open in a new tab.

Registrar

Details about the registrar of the issue.

Registrar Name
Kfin Technologies Limited
Phone
4067162222
Address
KFintech, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Gachibowli, Hyderabad, Telangana India - 500 032.

Issue details

Key details about the issue, including the face value, lot size, and minimum investment.

Issue Type
BB
Face Value
10
Lead Managers
Interactive Financial Services Ltd.
Min Quantity
164
Company Promoters
Punitkumar R. rasadia,Meet Atulkumar Vachhani,Mamata punitkumar Rasadia are the promoters of the company.
Phone
+91 281 2562538
Address
Anlon Healthcare Ltd. 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005

Related articles

Research posts and updates that reference this company or theme.

Follow IPO & unlisted research in the app, available on iOS and Android.